New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...

Merck estimates the project will create more than 500 full-time roles and about 4,000 construction jobs. CEO of Main Line ...

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.

This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily ...

Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA. RAHWAY, N.J., April 29, 2025--(BUSINESS WIRE)--Merck (NYS ...

Merck, the Pharma giant with operations in Lansdale, announced on Tuesday that it will build a $1 billion “biologics center ...

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...